1. Basic Information
Diseases Protected Against
- Measles — Airborne viral illness; characterized by high fever, cough, coryza, conjunctivitis, and a maculopapular rash. Complications include pneumonia, otitis media, encephalitis (1 per 1,000 cases), and subacute sclerosing panencephalitis (SSPE, ~4–11 per 100,000 cases). Case-fatality rate in developed countries: ~1–3 per 1,000 cases.
- Mumps — Viral illness causing parotitis; complications include orchitis (in ~25% of post-pubertal males), oophoritis, aseptic meningitis, and sensorineural hearing loss.
- Rubella — Generally mild viral illness with rash and lymphadenopathy. Primary concern is congenital rubella syndrome (CRS) when infection occurs during pregnancy, causing deafness, heart defects, cataracts, and developmental disability in the fetus.
CDC Recommended Schedule (United States, 2025)
| Dose | Recommended Age | Notes |
|---|---|---|
| Dose 1 | 12–15 months | MMR or MMRV (MMR + varicella) may be given |
| Dose 2 | 4–6 years | Routinely given before school entry |
| Catch-up | Any age ≥ 4 weeks after dose 1 | For those lacking evidence of immunity |
| Early dose (travel) | 6–11 months | Does not replace routine 2-dose series; given before international travel to measles-endemic areas |
Source: CDC Advisory Committee on Immunization Practices (ACIP), 2025 Child & Adolescent Immunization Schedule.
Licensed Products (U.S.)
- M-M-R® II (Merck & Co.) — Licensed 1978. Contains live attenuated measles (Enders' attenuated Edmonston strain), mumps (Jeryl Lynn strain), and rubella (Wistar RA 27/3 strain).
- PRIORIX (GlaxoSmithKline) — Licensed in the U.S. June 2022. Contains live attenuated measles (Schwarz strain), mumps (RIT 4385 strain, derived from Jeryl Lynn), and rubella (Wistar RA 27/3 strain).
- ProQuad® (MMRV) — MMR + varicella combination. Not reviewed separately on this page; safety signals differ (see Section 4).
2. Pre-Licensure Clinical Trial Data
M-M-R® II (Merck) — Pivotal Trials
The original MMR vaccine (M-M-R) was licensed in 1971; M-M-R® II (with a more stabilised rubella component) was licensed in 1978. The pivotal pre-licensure trials for M-M-R® II enrolled approximately 1,964 children across multiple studies, principally evaluating immunogenicity (seroconversion rates).
| Metric | Data | Evidence Strength |
|---|---|---|
| Total participants (combined trials) | ~1,964 children | Limited Small by modern standards |
| Age range | Primarily 12 months – 6 years | — |
| Duration of safety follow-up | 42 days post-vaccination (standard for the era) | Limited |
| Seroconversion (measles) | ~95–99% (hemagglutination inhibition titers) | Moderate |
| Seroconversion (mumps) | ~96–98% | Moderate |
| Seroconversion (rubella) | ~98–99% | Moderate |
PRIORIX (GSK) — Pivotal Trials for U.S. Licensure (2022)
PRIORIX was licensed in the U.S. based on six clinical trials that included a total of ~6,449 participants who received PRIORIX. The trials were conducted in multiple countries. Three studies compared PRIORIX to M-M-R® II. The primary immunogenicity endpoints were non-inferiority comparisons of seroresponse rates and geometric mean titers.
- Total PRIORIX recipients in safety population: ~6,449 (children 12 months – 6 years, plus a smaller adult cohort)
- Safety follow-up duration: 42 days for systemic adverse events; serious adverse events (SAEs) collected for 6 months
- Non-inferiority met for all three antigens vs. M-M-R® II
Most Common Adverse Reactions (Pre-Licensure Trials)
| Reaction | M-M-R® II (Approx.) | PRIORIX (Approx.) |
|---|---|---|
| Injection site pain / tenderness | ~15–25% | ~20–30% |
| Injection site redness | ~5–10% | ~8–15% |
| Fever ≥ 38.0°C (100.4°F) | ~5–15% | ~8–18% |
| Fever ≥ 39.4°C (103°F) | ~2–5% | ~1–3% |
| Rash (measles-like, morbilliform) | ~5% | ~3–4% |
| Irritability / fussiness | ~10–20% | ~12–22% |
| Upper respiratory symptoms | ~5–8% | ~4–7% |
Sources: M-M-R® II and PRIORIX prescribing information / FDA review documents. Frequencies vary by trial design, age group, and case definitions used.
Key Limitations of Pre-Licensure Trial Data
- Sample size: Pre-licensure trials are powered to detect common adverse events and demonstrate immunogenicity, not to detect rare but serious adverse events (e.g., those occurring at rates < 1 per 10,000 doses).
- Follow-up duration: Safety follow-up was limited to 42 days in most protocols, meaning long-term or delayed-onset adverse events could not be assessed.
- Exclusion criteria: Trials excluded children with significant pre-existing medical conditions, immunodeficiencies, and known allergies, limiting generalizability to those subpopulations.
- Demographics: Trial populations were not always fully representative of the demographic diversity of the U.S. population (particularly true for the older M-M-R® II trials conducted in the 1970s).
- No placebo arm: Most MMR trials used active comparators or open-label designs. True placebo-controlled data are limited.
3. Post-Licensure Safety Data
Vaccine Safety Datalink (VSD)
The VSD is a collaboration between the CDC and integrated healthcare organizations that monitor the electronic health records of approximately 9–10 million people annually (~3% of the U.S. population). It enables near-real-time active surveillance ("rapid cycle analysis") as well as retrospective cohort and case-control studies.
- Design: Active surveillance using electronic health records; includes both self-controlled case series analyses and cohort studies.
- Key VSD findings for MMR:
- Febrile seizures: Consistently observed increased risk in the 5–12 day window after MMR vaccination. VSD estimates: ~1 additional febrile seizure per 2,300–3,000 doses in children aged 12–23 months. Risk is higher with MMRV (ProQuad) compared to MMR + varicella given separately (~1 per 1,250 MMRV doses).
- ITP (Immune Thrombocytopenic Purpura): VSD self-controlled risk-interval analyses estimated approximately 1 case per 30,000–40,000 MMR doses in the 6-week post-vaccination window.
- Autism: Multiple large VSD cohort and case-control studies have not found an increased risk. The largest VSD study on this question (2004, DeStefano et al.) included >250,000 children.
- No association found: VSD studies have not identified statistically significant associations between MMR and ataxia, encephalopathy, or type 1 diabetes.
Sources: DeStefano et al. (2004) Pediatrics; Klein et al. (2010) Pediatrics; VSD annual surveillance reports (CDC).
VAERS (Vaccine Adverse Event Reporting System)
VAERS is a passive (spontaneous) reporting system co-managed by the CDC and FDA. VAERS cannot establish causation. Reports may be submitted by anyone and reflect unverified temporal associations. Underreporting is common; conversely, stimulated reporting can occur after media attention.
| VAERS Metric (MMR, cumulative data) | Approximate Figures |
|---|---|
| Total U.S. doses distributed (estimated, all MMR products, through ~2024) | >600 million doses |
| Total VAERS reports received for MMR | ~85,000 – 100,000 (cumulative) |
| Reports classified as "serious" (per CFR 600.80 criteria: death, life-threatening illness, hospitalization, disability, congenital anomaly) | ~8–10% of total MMR reports |
| Most commonly reported adverse events | Fever, rash, injection site reactions, pyrexia, irritability (consistent with clinical trial data) |
⚠ Critical Caveat
VAERS data represent unverified reports of events temporally associated with vaccination. A report to VAERS does not mean the vaccine caused the event. VAERS is designed to generate hypotheses and detect potential safety signals; it cannot be used to calculate incidence rates or establish causality. Any analysis that uses raw VAERS report counts as a measure of vaccine risk is scientifically invalid.
Major Independent Post-Licensure Reviews
| Review / Institution | Year(s) | Design & Scope | Key Finding |
|---|---|---|---|
| Institute of Medicine (IOM) — "Adverse Effects of Vaccines: Evidence and Causality" | 2012 | Systematic review of >12,000 peer-reviewed articles; consensus committee evaluated epidemiological and mechanistic evidence for 158 adverse event–vaccine pairs | Favors acceptance of a causal relationship for MMR and: measles inclusion body encephalitis (in immunocompromised), febrile seizures, anaphylaxis, and transient arthralgia (rubella component). Rejects causal association for MMR and autism, type 1 diabetes, and asthma. |
| Cochrane Systematic Review — "MMR Vaccine" (Demicheli et al.) | 2012 (updated 2020) | Meta-analysis of 138 randomized and quasi-randomized controlled trials, plus observational studies; N > 23 million children in observational studies | Effectiveness: 1-dose measles efficacy ~95%; 2-dose ~96%. Safety: No credible evidence of association with autism, asthma, leukemia, or multiple sclerosis. Identified febrile seizures and ITP as associated risks. |
| National Academies of Sciences, Engineering, and Medicine (NASEM) — "Vaccine Safety" | 2020 (targeted updates ongoing) | Review of safety data for the recommended childhood immunization schedule | No evidence that the recommended schedule is associated with adverse neurodevelopmental outcomes. |
| Danish Nationwide Cohort Study (Hviid et al., Annals of Internal Medicine) | 2019 | Population-based cohort: 657,461 children born in Denmark 1999–2010; up to 14 years follow-up | No increased risk of autism in MMR-vaccinated vs. unvaccinated children (HR 0.93; 95% CI 0.85–1.02). No increased risk in subgroups considered high-risk. |
The Wakefield Paper (1998) and Subsequent Investigation
A 1998 case series (n=12) by Wakefield et al., published in The Lancet, hypothesised an association between MMR, gastrointestinal disease, and autism. The paper was fully retracted by The Lancet in 2010 following a General Medical Council (UK) investigation that found Wakefield guilty of serious professional misconduct, including ethical violations and undisclosed financial conflicts of interest. Multiple large-scale epidemiological studies (see Section 6 and References) have since found no evidence of an association. This is noted here because the Wakefield paper was the primary origin of the MMR–autism hypothesis and continues to influence public perception despite retraction.
Confirmed Safety Signals Identified in Post-Licensure Data
- Febrile seizures — Observed in VSD, VAERS, and multiple international databases. Risk window: 5–12 days post-vaccination (coinciding with peak viremia from measles component).
- Immune Thrombocytopenic Purpura (ITP) — Signal identified through VSD and confirmed in multiple international studies. Typically transient and self-limited.
- Measles Inclusion Body Encephalitis (MIBE) — Rarely reported in severely immunocompromised individuals; confirmed causal by IOM.
- Febrile seizures at a higher rate with MMRV (ProQuad) compared to MMR + varicella given separately — Identified through VSD rapid cycle analysis, confirmed in post-marketing studies.
Note: Safety "signals" identified through post-licensure surveillance require further analytical epidemiological studies to confirm or refute causality. Signals may later be determined to be coincidental.
VAERS Reporting Data — Halma & Varon (2025), DARE-SAFE
The DARE-SAFE paper (Halma & Varon, Pharmacoepidemiology 2025, CC BY 4.0) analyzed VAERS reports for vaccines administered in the United States from 2006–2022. The following data are extracted from Table 1 of that paper for this vaccine (MMR combined (Measles, Mumps, Rubella; M-M-R II + PRIORIX)):
| Metric | Value |
|---|---|
| U.S. doses administered (2006–2022) | 134,424,338 |
| Total VAERS AE reports | 35,743 |
| AE reporting rate (per 100,000 doses) | 26.6 |
| Total death reports | 88 |
| Death reporting rate (per 100,000 doses) | 0.0655 |
| AE-to-Death ratio | 406:1 |
Source: Halma MT, Varon J. DARE-SAFE. Pharmacoepidemiology. 2025. DOI: 10.3390/pharma4010005. CC BY 4.0. Data from Table 1.
📚 Important Interpretive Caveats (from the paper itself)
- Reporting rate ≠ incidence rate. VAERS is a passive, unverified system. A report means someone submitted a claim of temporal association, not a confirmed causal event. The paper is explicit that causality cannot be inferred from these numbers alone.
- Reporting behavior is not uniform. More serious, unusual, or media-salient events are reported at much higher rates than mild ones. Products receiving more public, media, legal, and clinical attention (particularly COVID-19 vaccines, which also benefited from V-safe active-surveillance prompts and CICP compensation pathways) generate more reports per dose regardless of true risk.
- Age and comorbidity confounding is not adjusted. COVID-19 vaccines were disproportionately administered to elderly and comorbid populations (nursing homes, 65+, high-risk groups in early 2021) with much higher background all-cause mortality than the general child/working-age population. Some fraction of temporally-associated deaths would occur regardless of vaccination, and the paper does not perform a background-rate comparison.
- Stimulated reporting is a known, documented phenomenon. Media coverage, plaintiff attorney solicitation, and advocacy campaigns — all independently inflate VAERS reporting propensity. The paper cites this literature but does not correct for it.
- Small-denominator rows are unreliable. Rates computed from small denominators (e.g., monovalent measles, DT, mumps, rubella) have enormous statistical uncertainty and should not be compared to vaccines with hundreds of millions of administered doses without noting the wide confidence intervals.
Source: Halma MT, Varon J. DARE-SAFE: A data analysis and reporting engine for safety signal detection and pharmacovigilance. Pharmacoepidemiology. 2025;4(1):5. DOI: 10.3390/pharma4010005. CC BY 4.0.
4. Documented Adverse Events — Evidence of Association
▶ Adverse Events with Strong Evidence of Causal Association
Criteria: Consistent epidemiological data from multiple independent studies, supported by mechanistic plausibility, and reviewed by IOM / NASEM or equivalent authoritative body.
- Febrile seizures: Occurring at an estimated rate of ~1 per 2,300–3,000 doses in the 5–12 day post-vaccination window (MMR alone). Risk is elevated with MMRV (~1 per 1,250 doses). Most febrile seizures are self-limited and do not cause long-term neurological sequelae. Strong
- Immune Thrombocytopenic Purpura (ITP): Estimated at ~1 per 30,000–40,000 doses, typically within 6 weeks of vaccination. Usually transient; resolves spontaneously or with treatment in the majority of children. The risk is lower than the risk of ITP following natural measles or rubella infection. Strong
- Anaphylaxis: Estimated at 1–3 per million doses. Attributed to vaccine excipients (e.g., gelatin, neomycin). Standard contraindication for individuals with known severe allergic reaction to a prior dose or vaccine component. Strong
- Measles Inclusion Body Encephalitis (MIBE): Documented in severely immunocompromised individuals (e.g., those with advanced HIV, congenital immunodeficiency). Extremely rare. Strong
- Transient arthralgia / arthritis: Associated with the rubella component (RA 27/3 strain). Reported in ~10–25% of susceptible adult women vaccinated post-puberty; usually mild and self-limited. Much less common in children. Strong
- Parotitis / lymphadenopathy: Mild, transient swelling of parotid gland or lymph nodes, attributable to the mumps and rubella vaccine virus components respectively. Strong
▶ Adverse Events with Moderate or Preliminary Evidence
Criteria: Some epidemiological evidence consistent with a signal, but data are limited by sample size, inconsistent findings across studies, or insufficient mechanistic evidence.
- Aseptic meningitis: Associated with older mumps vaccine strains containing the Urabe Am9 strain (not used in the U.S.). The Jeryl Lynn and RIT 4385 strains used in U.S.-licensed MMR vaccines have not been consistently associated with aseptic meningitis. Residual evidence is considered insufficient to rule out a very rare association. Moderate (for Urabe strain; Limited for Jeryl Lynn / RIT 4385)
- Encephalopathy / encephalitis (in immunocompetent individuals): Case reports exist but large-scale epidemiological studies have not consistently demonstrated an association beyond background rates. IOM (2012) concluded that evidence "favors rejection" of a causal relationship for MMR and encephalopathy in immunocompetent individuals, but noted some evidence for a rare association with encephalitis in immunocompromised. Preliminary
- Guillain-Barré Syndrome (GBS): Isolated case reports exist; no consistent signal in large epidemiological studies. IOM (2012) concluded evidence is inadequate to accept or reject a causal relationship. Limited
- Chronic arthropathy: Some studies have suggested a possible association between rubella vaccination and persistent joint symptoms, but evidence is inconsistent. IOM determined the evidence was inadequate. Preliminary
▶ Published Evidence Does Not Support a Causal Association
Criteria: Multiple large, well-controlled epidemiological studies have consistently failed to find an association; IOM / NASEM has rejected a causal relationship; or the preponderance of high-quality evidence is against an association.
- Autism Spectrum Disorder (ASD): Evidence against a causal association is extensive. Major studies include:
- Danish nationwide cohort (Hviid et al., 2019): N=657,461; HR 0.93 (95% CI 0.85–1.02)
- VSD case-control study (DeStefano et al., 2004): N > 250,000
- Japanese cohort study (Honda et al., 2005): N=31,426; no MMR–ASD association
- UK case-control study (Smeeth et al., 2004): N=1,294 ASD cases; OR 0.86 (95% CI 0.68–1.08)
- Canadian cohort (Fombonne et al., 2006): N=27,749
- Meta-analysis (Taylor et al., 2014): 10 studies, >1.2 million children; no association
- Type 1 Diabetes Mellitus: Multiple cohort and case-control studies, including a 10-year Danish cohort of >700,000 children, have not found an association. IOM (2012) favored rejection of causality. No Association
- Inflammatory Bowel Disease (IBD): Studied extensively following the Wakefield hypothesis; multiple large epidemiological studies have not found an association. IOM rejected causality. No Association
- Asthma: Several large cohort studies have not identified an association. IOM (2012) favored rejection of causality. No Association
- Multiple Sclerosis: No consistent epidemiological evidence for an association. No Association
- Leukemia: Multiple studies have not identified an association. Some studies have suggested MMR may be associated with a reduced risk of childhood leukemia, though this finding is not consistent. No Association
5. Disease Prevention Benefits
5a. Measles — Pre-Vaccine vs. Post-Vaccine Era (United States)
| Metric | Pre-Vaccine Era (Annual Average, ~1958–1962) | Post-Vaccine Era (Annual, 2010–2024) |
|---|---|---|
| Estimated cases | ~3–4 million (500,000 reported annually) | <1,300 (range: 13 cases in 2020 to 1,274 in 2019); majority importation-linked |
| Hospitalizations | ~48,000 | Fewer than 100 most years; 128 in the 2019 outbreak |
| Deaths | ~400–500 | 0–2 most years; 0 deaths in the 2019 outbreak |
| Encephalitis cases | ~1,000 | <5 most years |
| SSPE cases | ~40–100 per year (estimated) | Extremely rare (<5 per year) |
| U.S. elimination status | — | Declared eliminated in 2000. Elimination status has been threatened by outbreaks in 2014, 2019, and 2024–2025. |
Source: CDC MMWR surveillance summaries; CDC Pink Book (Measles chapter). Reported cases underestimate true incidence; pre-vaccine era case estimates are ~10x higher than reported cases because measles was ubiquitous.
5b. Mumps — Pre-Vaccine vs. Post-Vaccine Era (United States)
| Metric | Pre-Vaccine Era (Annual Average, ~1967) | Post-Vaccine Era (Annual, 2010–2024) |
|---|---|---|
| Reported cases | ~186,000 | <6,200 (range: 229 in 2012 to 6,109 in 2016) |
| Deaths | ~20–30 | <5 per year |
| Encephalitis | ~200–400 cases | Very rare (<10 per year) |
Source: CDC MMWR; CDC Pink Book (Mumps chapter). Note: Mumps outbreaks continue to occur in highly vaccinated populations, particularly in close-contact settings (colleges, sports teams), likely due to waning immunity and less-than-perfect 2-dose effectiveness (~88%, range 79–95%).
5c. Rubella and Congenital Rubella Syndrome — Pre-Vaccine vs. Post-Vaccine Era (United States)
| Metric | Pre-Vaccine Era (1964–1965 Epidemic as Reference) | Post-Vaccine Era |
|---|---|---|
| Rubella cases (epidemic year) | ~12.5 million (1964–1965) | <10 reported cases annually since 2010; rubella declared eliminated in the Americas in 2015 |
| CRS cases (epidemic) | ~20,000 infants with CRS (1964–1965) | 0–1 per year; last known U.S.-acquired CRS case reported in 2012 |
| Deaths (rubella/CRS) | ~2,100 neonatal deaths; ~11,000 fetal losses (1964–1965) | <5 per year |
Source: CDC Pink Book (Rubella chapter); PAHO rubella elimination declaration (2015).
Current Disease Burden & Outbreak Context
- Measles: As of 2024–2025, the U.S. has experienced a resurgence of measles cases linked to international importation, primarily affecting unvaccinated individuals and communities with suboptimal vaccination coverage. The CDC reported over 280 cases in the first quarter of 2025 alone — exceeding the total for any full year since 2019. Most cases (>90%) occurred in unvaccinated persons or persons with unknown vaccination status.
- Mumps: Sporadic outbreaks continue, predominantly in vaccinated populations in high-density settings. The 2-dose MMR series has an estimated effectiveness against mumps of ~88% (range across studies: 79–95%), lower than the >95% observed in pre-licensure serological studies — attributed to waning immunity over time and potential antigenic differences between vaccine and circulating wild-type strains.
- Rubella: Endemic transmission has been interrupted in the U.S. since 2015, and no U.S.-acquired CRS cases have been reported since 2012. Imported cases continue to be detected occasionally.
6. Evidence Summary — Overall Assessment
Quality and Quantity of Safety Data
The MMR vaccine is one of the most extensively studied vaccines in terms of post-licensure safety. The body of evidence includes:
- >138 controlled trials included in the Cochrane systematic review.
- Observational studies encompassing >23 million children across multiple countries.
- Active surveillance of ~9–10 million people per year through VSD.
- Passive surveillance (VAERS) spanning decades with >85,000 reports.
- Independent, comprehensive reviews by IOM (2012), Cochrane Collaboration (2012, updated 2020), and NASEM.
Areas Where Data Are Robust
- Effectiveness: Large bodies of observational and trial data consistently find 1-dose measles effectiveness of ~93–95% and 2-dose effectiveness of ~96–97%. Mumps effectiveness is lower (~78–88% for 2 doses in outbreak settings). Rubella effectiveness is ~95–99%.
- Febrile seizures: The risk, magnitude, and timing are well-characterised across multiple surveillance systems and study designs.
- ITP: The association is consistently identified across multiple independent studies, with a well-characterised risk magnitude.
- Absence of MMR–autism association: This is one of the most thoroughly studied hypotheses in vaccine safety. The evidence against an association is extensive, consistent, and derives from multiple independent study designs across multiple countries.
- Anaphylaxis: Well-documented, with established risk estimates.
Areas Where Data Are Limited or Conflicting
- Rare neurological events: For events occurring at rates <1 per million doses (e.g., encephalitis, GBS), even large surveillance systems may be underpowered to detect or exclude small increases in risk. Evidence is insufficient to draw firm conclusions in either direction for several of these outcomes.
- Long-term autoimmune outcomes: Studies of chronic autoimmune conditions potentially triggered by vaccination are methodologically difficult (long latency, diagnostic challenges, confounding). Data on some conditions (e.g., chronic arthropathy following rubella vaccination) remain inconsistent.
- MMR in immunocompromised populations: These individuals are excluded from most clinical trials and are inherently difficult to study in observational designs due to heterogeneity and confounding by underlying disease. Safety data for this population rely largely on case reports and small case series.
- MMRV-specific risks: The elevated risk of febrile seizures with MMRV relative to MMR + varicella is well-documented. Other potential differences in safety profiles between MMRV and separately administered MMR and varicella vaccines have been less thoroughly studied.
- Mumps component durability: Observational data suggest waning immunity after the second dose; the optimal timing for a potential third dose in outbreak settings remains under investigation.
Overall Summary Table
| Domain | Evidence Grade | Key Finding |
|---|---|---|
| Measles protection (1 dose) | Strong | ~93–95% effective |
| Measles protection (2 doses) | Strong | ~96–97% effective |
| Mumps protection (2 doses) | Strong | ~78–88% effective in outbreak settings; waning over time documented |
| Rubella protection | Strong | ~95–99% effective |
| Febrile seizures | Strong | ~1 per 2,300–3,000 doses (MMR); higher with MMRV |
| ITP | Strong | ~1 per 30,000–40,000 doses |
| Anaphylaxis | Strong | ~1–3 per million doses |
| Autism spectrum disorder | No Association | Extensively studied; IOM rejects causality; multiple large studies show no association |
| Encephalopathy (immunocompetent) | Preliminary | Evidence against association, but rare events difficult to rule out |
| Guillain-Barré Syndrome | Limited | Inadequate data to confirm or refute; isolated case reports |
| Long-term autoimmune outcomes | Preliminary | Data inconsistent; further research needed |
7. Key References
References are organised by category. Links are provided to the original source where available.
Pre-Licensure Trials / FDA Review Documents
- Merck & Co., Inc. M-M-R® II (Measles, Mumps, and Rubella Virus Vaccine Live) — Prescribing Information. merck.com/product/usa/pi_circulars/m/mmr_ii/mmr_ii_pi.pdf
- GlaxoSmithKline. PRIORIX (Measles, Mumps, and Rubella Vaccine, Live) — Prescribing Information. gskpro.com
- FDA. Clinical Review — PRIORIX (BLA 125759), 2022. fda.gov/vaccines-blood-biologics/vaccines/priorix
Systematic Reviews & Meta-Analyses
- Demicheli V, Rivetti A, Debalini MG, Di Pietrantonj C. Vaccines for measles, mumps and rubella in children. Cochrane Database of Systematic Reviews. 2012 (updated 2020). DOI: 10.1002/14651858.CD004407.pub3
- Taylor LE, Swerdfeger AL, Eslick GD. Vaccines are not associated with autism: an evidence-based meta-analysis of case-control and cohort studies. Vaccine. 2014;32(29):3623–3629. DOI: 10.1016/j.vaccine.2014.04.085
- Pietrantonj CD, Rivetti A, Marchione P, Debalini MG, Demicheli V. Vaccines for measles, mumps, rubella, and varicella in children. Cochrane Database Syst Rev. 2020. DOI: 10.1002/14651858.CD004407.pub4
Institute of Medicine / National Academies Reports
- Institute of Medicine. Adverse Effects of Vaccines: Evidence and Causality. Washington, DC: The National Academies Press; 2012. nationalacademies.org
- Committee on the Assessment of Studies of Health Outcomes Related to the Recommended Childhood Immunization Schedule. The Childhood Immunization Schedule and Safety: Stakeholder Concerns, Scientific Evidence, and Future Studies. National Academies Press; 2013.
Major Post-Licensure Observational Studies
- Hviid A, Hansen JV, Frisch M, Melbye M. Measles, Mumps, Rubella Vaccination and Autism — A Nationwide Cohort Study. Annals of Internal Medicine. 2019;170(8):513–520. DOI: 10.7326/M18-2101
- DeStefano F, Bhasin TK, Thompson WW, et al. Age at first measles-mumps-rubella vaccination in children with autism and school-matched control subjects. Pediatrics. 2004;113(2):259–266. DOI: 10.1542/peds.113.2.259
- Klein NP, Fireman B, Yih WK, et al. Measles-mumps-rubella-varicella combination vaccine and the risk of febrile seizures. Pediatrics. 2010;126(1):e1–e8. DOI: 10.1542/peds.2010-0665
- Fombonne E, Zakarian R, Bennett A, et al. Pervasive developmental disorders in Montreal, Quebec, Canada: prevalence and links with immunizations. Pediatrics. 2006;118(1):e139–e150. DOI: 10.1542/peds.2005-2993
- Smeeth L, Cook C, Fombonne E, et al. MMR vaccination and pervasive developmental disorders: a case-control study. The Lancet. 2004;364(9438):963–969. DOI: 10.1016/S0140-6736(04)17020-7
- France EK, Smith-Raymond L, Xu S, et al. Risk of immune thrombocytopenic purpura after measles-mumps-rubella immunization in children. Pediatrics. 2008;121(3):e687–e692. DOI: 10.1542/peds.2007-1578
Official Surveillance and Public Health References
- CDC. Epidemiology and Prevention of Vaccine-Preventable Diseases (The Pink Book) — Measles, Mumps, Rubella chapters. cdc.gov/pinkbook
- CDC. Vaccine Safety Datalink (VSD). cdc.gov/vaccine-safety/about/vsd.html
- CDC/FDA. Vaccine Adverse Event Reporting System (VAERS). vaers.hhs.gov
- CDC. 2025 Child & Adolescent Immunization Schedule. cdc.gov/vaccines/hcp/imz-schedules
- CDC. Measles Cases and Outbreaks (current surveillance). cdc.gov/measles/data-research
- Wakefield AJ, Murch SH, Anthony A, et al. Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children. The Lancet. 1998;351(9103):637–641. RETRACTED (2010). DOI: 10.1016/S0140-6736(97)11096-0 (retracted)
- Halma MT, Varon J. DARE-SAFE: A data analysis and reporting engine for safety signal detection and pharmacovigilance. Pharmacoepidemiology. 2025;4(1):5. DOI: 10.3390/pharma4010005. CC BY 4.0.